Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis

A carbon monoxide and sepsis technology, used in the treatment of coagulation disorders in sepsis. Carbon monoxide releasing molecules combined with ultra-micro-dose heparin can solve problems such as coagulation damage and achieve easy and correct control of dosage and concentration. , to meet the effect of clinical application

Inactive Publication Date: 2012-09-05
AFFILIATED HOSPITAL OF JIANGSU UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, single use of large doses of heparin in sepsis can cause greater damage to coagulation function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis
  • Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis
  • Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Preparation of the drug:

[0022] Mix 20.5 mg of carbon monoxide releasing molecules with 1 ml of DMSO to obtain a 40 mM preparation A, which is used at a dose of 8 mg / kg body weight; mix 20,000 IU / 2 ml of heparin with normal saline and dilute 10 times to obtain 1000 IU / L Heparin solution preparation B is used at a dose of 100IU / kg body weight.

Embodiment 2

[0024] The effects of CORM-2+ ultramicro-dose heparin on WBC, PLT count, plasminogen (PLG) and antithrombin III (AT-III) activities in septic mice.

[0025] experiment method:

[0026] (1) Animal and CLP sepsis models

[0027] Male C57BL / 6 mice, 6-8 weeks old, weighing 18±2 grams, are raised in ordinary laboratories (commercial dry block material, free drinking water). The experimental animals were divided into three groups according to the random number table method: Sham group (n=9), CLP group (n=9) and CLP+CORM-2+heparin group (n=9).

[0028] Under isoflurane inhalation anesthesia, mice in the CLP group underwent cecal ligation and perforation. After injury, 1.5ml normal saline was injected into the abdominal cavity for anti-shock; the mice in the CLP+CORM-2+heparin group were injected with CORM-2(8mg) after CLP. / kg), and at the same time intraperitoneal injection of heparin 100U / kg body weight.

[0029] Among them, the medicine used in the Sham group is normal saline, the medicin...

Embodiment 3

[0050] The effect of CORM-2+ ultra-micro-dose heparin on blood coagulation system and platelet aggregation in septic mice

[0051] experiment method:

[0052] (1) Animal and CLP sepsis models

[0053] Male C57BL / 6 mice, 6-8 weeks old, weighing 18±2 grams, are raised in ordinary laboratories (commercial dry block material, free drinking water). The experimental animals were divided into three groups according to the random number table method: Sham group (n=9), CLP group (n=9) and CLP+CORM-2+heparin group (n=9). Under isoflurane inhalation anesthesia, mice in CLP group underwent cecal ligation and perforation. After injury, 1.5ml normal saline was injected into the abdominal cavity for anti-shock; mice in CLP+CORM-2+heparin group were injected with CORM-2(8mg) after CLP. / kg), and at the same time intraperitoneal injection of heparin 100U / kg body weight. All animals were killed by inhalation of isoflurane 24 hours after injury, and specimens were collected.

[0054] (2) Testing indi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of carbon monoxide-releasing molecules and heparin in preparing a medicament for treating sepsis. The carbon monoxide-releasing molecules are combined with the ultramicro heparin to improve the coagulation defects of the sepsis, the control of the concentration of the carbon monoxide-releasing molecules and the heparin is relatively easy and correct, the carbon monoxide-releasing molecules and the heparin can be conveniently added when used for a long time, simultaneously the consumption and side effect of the heparin are reduced, and the carbon monoxide-releasing molecules and the heparin can meet the requirement of clinical application. The carbon monoxide-releasing molecules are combined with the ultramicro heparin to improve the coagulation defects of the sepsis, the control of the concentration of the carbon monoxide-releasing molecules and the heparin is relatively easy and correct, the carbon monoxide-releasing molecules and the heparin can beconveniently added when used for a long time, and the carbon monoxide-releasing molecules and the heparin can meet the requirement of clinical application.

Description

Technical field [0001] The present invention relates to a new use of carbon monoxide releasing molecules and heparin, in particular to a kind of carbon monoxide releasing molecules combined with ultrafine dose heparin, and early application of drugs for treating blood coagulation dysfunction in sepsis. Background technique [0002] Sepsis is a common complication after severe trauma, shock and infection. Further development can lead to septic shock and multiple organ dysfunction syndrome (MODS). Even in the modern era where basic and clinical medical research and intensive care methods are highly developed, Clinical treatment still has little effect, and the mortality rate remains high. Studies have shown that the mortality rate of important organ failure, especially multiple organ failure after severe sepsis, is very high. Once multiple organ failure occurs, it is difficult to reverse it with existing treatment measures, so it is particularly important to prevent or reduce orga...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/727A61P7/04A61P31/00A61P43/00
Inventor 孙炳伟刘东明陈曦
Owner AFFILIATED HOSPITAL OF JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap